Login
$RGNX
$7.32 -$0.32 (4.19%) Live

$RGNX SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027

03 Nov 2026 Form 4: Malzahn Craig, Chief Technology Officer

Received 27,777 shares as a grant or award

03 Nov 2026 Form 4: Christmas Patrick J., Chief Strategy & Legal Officer

Received 34,722 shares as a grant or award

03 Nov 2026 Form 4: Pakola Steve, Chief Medical Officer

Received 34,722 shares as a grant or award

03 Nov 2026 Form 4: Chan Mitchell, Chief Financial Officer

Received 24,305 shares as a grant or award

16 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to fo...

13 Oct 2026 SCHEDULE 13G
23 Sep 2026 8-K: Entry into a Material Definitive Agreement

On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta Therapeutics ...

03 Sep 2026 Form 4: Malzahn Craig, Chief Technology Officer

Gave up 234 shares to cover exercise price or tax ($2.18K)

03 Sep 2026 Form 4: Chan Mitchell, Chief Financial Officer

Gave up 4,902 shares to cover exercise price or tax ($45.7K)

27 Aug 2026 Form 4: Ciongoli Gregory Austin, Director

Received 15,432 shares as a grant or award · Granted 69,609 Stock Options (Right to buy) · Bought 49,196 shares ($450K) · 1 more

27 Aug 2026 Form 3: Ciongoli Gregory Austin, Director

No securities owned

25 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

ROCKVILLE, Md., August 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of pot...

24 Aug 2026 8-K: Regulation FD Disclosure; Other Events

ROCKVILLE, Md., August 24, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as ...

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027

04 Aug 2026 Form 4: Pakola Steve, Chief Medical Officer

Gave up 7,468 shares to cover exercise price or tax ($72.4K)

04 Aug 2026 Form 4: Christmas Patrick J., Chief Strategy & Legal Officer

Gave up 4,699 shares to cover exercise price or tax ($45.5K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support